Evaluating progression-free survival of EGFR exon 20ins in patients with advanced non-small lung cancer receiving EGFR inhibitors: A real-world data study

被引：0
|
作者：
Kabbaha, Suad [1 ]
Dempsey, Sarah Carder [1 ]
Thorlund, Kristian [1 ]
机构：
[1] BioSpark AI Technol, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20092
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
    Chie Morita
    Tatsuya Yoshida
    Masayuki Shirasawa
    Ken Masuda
    Yuji Matsumoto
    Yuki Shinno
    Shigehiro Yagishita
    Yusuke Okuma
    Yasushi Goto
    Hidehito Horinouchi
    Noboru Yamamoto
    Noriko Motoi
    Yasushi Yatabe
    Yuichiro Ohe
    Scientific Reports, 11
  • [22] EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
    Yang, Guangjian
    Li, Jun
    Xu, Haiyan
    Yang, Yaning
    Yang, Lu
    Xu, Fei
    Xia, Bing
    Zhu, Viola W.
    Nagasaka, Misako
    Yang, Yan
    Li, Yapin
    Qiu, Weini
    Ying, Jianming
    Oug, Sai-Hong Ignatius
    Wang, Yan
    LUNG CANCER, 2020, 145 : 186 - 194
  • [23] EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes
    Xu, Haiyan
    Yang, Guangjian
    Li, Weihua
    Li, Junling
    Hao, Xuezhi
    Xing, Puyuan
    Yang, Yaning
    Wang, Yan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] Real-world outcomes of anti-EGFR therapy in advanced non-small cell lung cancer EGFR mutated in Peru
    Galvez-Nino, Marco
    Ruiz, Rossana
    Roque, Katia
    Coanqui, Ofelia
    Valdivieso, Natalia
    Olivera, Mivael
    Ganti, Apar Kishor
    Mas, Luis
    THORACIC CANCER, 2023, 14 (01) : 61 - 67
  • [25] EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations - real world data
    Dulloo, Sean
    Almusarhed, Manar
    Chen, Ryan
    Akala, Oyeyemi
    Varadhan, Balaji
    Chauhan, Meera
    Ahmed, Samreen
    LUNG CANCER, 2021, 156 : S40 - S40
  • [26] Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations
    Li, Jiaqi
    Xie, Mengqing
    Zhao, Ruiying
    Qiang, Huiping
    Chang, Qing
    Qian, Jialin
    Lu, Haijiao
    Shen, Yinchen
    Han, Yuchen
    Su, Chunxia
    Chu, Tianqing
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [27] Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis
    Zhang, Mai
    Huang, Qian
    Yu, Min
    Xue, Jianxin
    Huang, Meijuan
    Lu, You
    Zhang, Yan
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (04) : 797 - 807
  • [28] Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations
    Chen, Chi-Han
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Hsu, Ping-Chih
    Wu, Chiao-En
    ANTICANCER RESEARCH, 2022, 42 (04) : 2145 - 2157
  • [29] A Progression Free Survival Score for EGFR Mutant Non-Small Cell Lung Cancer Patients Treat with First Line EGFR Tyrosine Kinase Inhibitors
    Chen, Yu-Mu
    Lin, Meng-Chih
    Fang, Wen-Feng
    Lie, Chien-Hao
    Chang, Huang-Chih
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S276 - S277
  • [30] Real-world treatment duration in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations receiving mobocertinib through the global Expanded Access Program (EAP)
    Lee, V. H. F.
    Lin, M.
    Curran, E.
    Yin, Y.
    Churchill, E.
    Allen, S.
    Abovich, J.
    Leighl, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1059 - S1059
12345